INTRODUCTION 1
immunized according to a 2, 3, 4 month schedule, probably as a result of low transmission 1 and continued herd immunity. It is uncertain how long these herd effects may last. 2 Seroprevalence studies can be used to improve our understanding of population immunity and 3 to identify groups who are likely to be susceptible to serogroup C meningococcal infection 4 should herd protection wane. 5 6 We previously reported the seroprevalence of SBA to serogroup C meningococci in the pre-7 vaccine era. (28) . This earlier serosurvey used the same laboratory methods to test residual 8 sera from the same populations and as the present study, and thus provides a baseline measure 9 of 'natural' immunity, against which we can compare population immunity in the presence of 10 MCC vaccination. Here, we examined the age-specific seroprevalence profile for bactericidal 11 serogroup C antibodies using sera collected in the post-vaccination era between 2000 and 12
2004. In addition, we also measured IgG antibodies against Neisseria meningitidis serogroups 13 A, C, W-135 and Y. 14 
15

MATERIALS AND METHODS 16
Serum samples 17
Sera were obtained from the Health Protection Agency (HPA) Seroepidemiology Unit. This 18 collection is described fully elsewhere (22) , but briefly, participating laboratories submit 19 residual sera from routine diagnostic testing to the collection. Samples are anonymized, a 20 unique identity number is assigned and details regarding the age and sex of the donor, year of 21 collection and the participating laboratory are collated on a database. The reason why the 22 blood sample was taken is not documented, but immunocompromized individuals are 23 excluded. 24 Sera were tested using standardized complement-mediated SBA against O-acetylated 17 serogroup C strain C11 (C:16:P1.7-1,1) as previously described (17) . The complement source 18 was pooled 3-4 week old baby rabbit serum (Pel-Freeze Biologicals WI, USA). SBA titers 19
25
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were expressed as the reciprocal of the final serum dilution giving ≥ 50% killing at 60 20 minutes. SBA titers <4 were assigned a value of 2 for computational purposes. Results were 21 obtained for 2391 samples. below this threshold, a value equal to half the lower limit of detection was assigned for 7 computational purposes. Results were obtained for 2658 samples. 8 9
Statistical Analysis 10
Results from the serologic analyzes were linked to information on the age and sex of the 11 donor. The age of the serum donor and the year of sample collection were used to infer the 12 age and time at which MCC vaccination is likely to have been offered, according the routine 13 and catch-up immunization schedule (19) . Since all samples were anonymized, it was not 14 possible to collect information on immunization status. The percentage of individuals, by age, 15 with SBA titers ≥8 was calculated, together with 95% confidence intervals (95% CI). For 16 individuals aged less than 20 years, the age-specific prevalence of SBA titers ≥8 against 17 serogroup C meningococci was compared according to the age at vaccination/ schedule that 18 the group was eligible to have received and the time since vaccination was offered (within 2 19 years, or after 2 years or more). A two-sample, two-sided z-test was used to assess the 20 equality of proportions. The geometric mean concentrations (GMC) of serogroup-specific IgG 21
were calculated, by age, with corresponding 95% CI. The correlation between serogroup C 22
IgG and SBA titers in individuals was assessed using the Spearman's rho statistic. Data were 23 analyzed using Stata version 10.0. 24
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Comparison with pre-vaccine study 1
The age-specific prevalence of SBA to serogroup C between 2000 -2004 was compared with 2 the results of a previously published seroprevalence study from the pre-vaccine era (28) . This 3 earlier study used the same source of sera (the HPA seroepidemiology collection, described 4 above) and the same standardized laboratory methods, performed by the same laboratory. 
RESULTS
13
The cross-sectional age-specific prevalence of SBA titers ≥8 in the post-vaccine era is shown 14 in figure 1 , and compared with the seroprevalence profile before the introduction of MCC 15 vaccines. In those aged under 20 years (the main age range targeted in the MCC campaign), 16 the percentage with SBA titers ≥8 is higher in the post-vaccine compared to pre-vaccine era 17 (p<0.001 for all age-groups). In sera collected from infants less than one year old, 63.1% 18 (95% CI 51.9 to 73.4%) achieved protective titers in 2001-2004, with a higher proportion 19 (p<0.001) with SBA titers ≥8 in those aged 6-11 months compared to <6 months (figure 1). In 20 children aged 1-4 years, the percentage with protective titers is lower than observed in infants 21 at 35.4% (95% CI 31.6% to 39.4%, p<0.001). In older children, the percentage with 22 protective titers increases, and in 10-14 and 15-19 year olds, the prevalence of SBA titers ≥8 23 is around 67%. In sera collected from those aged 25 to 64 years prevalence is similar to that in 24 the pre-vaccine era (as shown by overlapping confidence intervals in figure 1 ). In those aged 25 The percentage of children with protective titers stratified by both age at and time since 4 scheduled vaccination is shown in figure 2 . In children scheduled for immunization in infancy 5 at 2, 3, 4 months, the percentage with SBA ≥8 declines from 74.6% within 18 months to 6 36.2% 18 months or more after vaccination was scheduled (p<0.001). In children offered 7 vaccine at older ages, no significant differences are observed according to time since 8 immunization. The proportion of children achieving (and maintaining) SBA titers ≥8 is higher 9 in those offered vaccine at older ages (5 and above) compared to those offered vaccine at 1-4 10 years of age (as shown by non-overlapping confidence intervals in figure 2) . 11
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The serogroup and age-specific IgG GMCs are shown in figure 3 . For serogroup C, the 13 distribution of GMCs by age are broadly similar to that for SBA titers, and is consistent with We have described the age-specific prevalence of SBA and IgG antibodies to serogroup C 3 meningococci in the English population following the introduction of MCC vaccines. As 4 anticipated, a higher proportion of individuals achieved SBA titers ≥8 in all age groups 5 targeted for MCC immunization compared to the pre-vaccine seroprevalence profile. We 6 observed variations in the proportions achieving putative protective titers according to 7 vaccine schedule offered, in particular the age at which vaccination was scheduled. In the 8 children targeted for routine immunization at 2, 3, 4 months, we observed that the prevalence 9 of putative protective SBA titers declined with time since vaccination. Previous studies have 10
shown that antibody persistence is poor after MCC immunization in infancy (at 2, 3, 4 11 months) and in children immunized at a young age (less than 2 years) in the catch-up 12 campaign (4, 26 ). This appears to be reflected in our results, where only 32% of children aged 13 1-4 years had SBA titers ≥8. For those targeted in the catch-up campaign, a higher percentage 14 of children had SBA titers ≥8 if they were offered vaccine at 5 -17 years of age, compared to 15 those targeted at 1-4 years of age. This is consistent with estimates of vaccine effectiveness in 16 England, which suggested that protection was higher, and more persistent, in those 17 immunized above the age of 3 years, compared to 1-2 years old (29) , and with higher 18 coverage in the school-based cohorts compared to pre-school children aged 2-5 years (32) . 19 Furthermore, studies of antibody persistence after vaccination have shown greater persistence 20 when vaccine was administered at older ages (26, 27) . 21 
22
The results of this cross-sectional study are compatible with those observed in studies that 23 have followed cohorts of vaccinated children over time. Snape and colleagues reported that of 24 94 children who were immunized with a single dose of MCC around 2 years of age, 37% had 25 an SBA titer ≥8 a median of 1.8 years after immunization (26) . In a further study, 987 1 children who had received 1 dose of MCC at age 6 to 15 years were followed up for a median 2 of five years after immunization. Among these children 84% had an SBA titer ≥8 (27) . This is 3 slightly higher than observed in our study, consistent with our study being an unselected 4 population sample that will have included some unvaccinated children. These results further 5 highlight the importance of age at immunization in determining antibody persistence. 6 7 In adults aged 25 years and older, the percentage of sera with SBA titers ≥8 was similar in the 8 pre-and post-vaccine era, with the exception of those aged 65 years and older, where 9 significantly fewer achieved protective SBA titers post-vaccination. As shown with Hib, the 10 reduction in natural boosting due to lower transmission after vaccine introduction could 11 increase susceptibility in unvaccinated adults (18) . However, since these samples were 12 collected in 2000, less than one year after vaccine introduction, it seems unlikely that such an 13 effect would be observed so quickly, and the reasons for this difference are unclear. 14 
15
The SBA assay is the accepted surrogate of protection for meningococcal disease (3), but 16 examination of serogroup-specific IgG levels can also be informative. In our study, serogroup 17 C specific IgG GMC followed a similar age-specific pattern to SBA in general, with higher 18 GMC observed in infants, comparatively lower GMC in 1-9 year olds, and then higher and disease is also uncommon in this setting (8, 16) ,and the age-distribution is flatter than 1 would be expected from the age-specific patterns of meningococcal carriage the high GMCs 2 reported here may be attributable to the presence of cross-reacting antigens (9, 21, 25) . 3 4 The sera used in this study were obtained through convenience rather than random sampling, 5 by collecting residual sera from routine diagnostic testing. This collection has been widely 6 used in epidemiologic studies (for example (6, 11,20,31,33,34) ). One disadvantage of this 7 collection is that, to preserve anonymity, few details are available regarding the individuals 8 from whom the sera were collected. We were unable to ascertain MCC immunization status 9 of the individuals in this study, so we could only infer likely vaccine coverage based on 10 national data. Routine MCC coverage remains high (over 90%) and coverage in the catch-up 11 campaign was also high (84% in children aged 12-23 months, 76% in children aged 2-5 years, 12 85% in school aged children) (32) . Selection bias in the serum collection is thought to be 13 limited because all individuals in the UK have free access to comprehensive healthcare. routine schedule, or in the 1-4 year old catch-up campaign) is of some concern, but it is 6 important to note that the incidence of serogroup C disease remains very low. Indirect vaccine 7 protection is clearly very important in this sustained reduction in serogroup C disease. 8
Mathematical models suggest that herd immunity persists for several years, and that 9 serogroup C circulation will increase only slowly after reaching its nadir (30) . These 10 predictions are consistent with post-licensure disease surveillance to date, however, these 11 models do not account for possible introductions of more transmissible or more virulent 12 serogroup C strains from outside of the UK. Continued high quality disease surveillance is 13 essential, but repeat seroprevalence surveys will also be useful to inform vaccine policy, in 14 order to identify susceptible cohorts, should herd immunity wane. 
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